Apricity Health

Founded in 2016 and headquartered in Chicago, PatientIQ is a patient-outcomes intelligence platform integrated with 50+ EHR systems. It helps hospitals, specialty practices and medtech/life-science companies systematically capture and analyze patient-reported outcomes. It serves more than 870 healthcare organizations across 20+ medical specialties, with a network covering 17 million patients and over 70 million captured outcomes; customers include Northwell Health, Sutter Health, Mercy and Johnson & Johnson.

Network Bio is a Palo Alto, California biotechnology company founded in 2022 that builds disease-specific AI models from human biological data. Its vertically integrated platform combines a biological research network that sources, links and structures tissue, blood and longitudinal clinical outcomes from leading U.S. academic medical centers (Mass General Brigham, University of Pennsylvania, Duke University, University of Colorado Anschutz and UCSF, spanning 500,000+ patients across oncology, immunology, metabolic and cardiovascular disease) into AI-ready datasets, with a bio-native AI architecture purpose-built to learn from multimodal biological data, overcome technical confounders and batch effects, and generate interpretable representations of disease biology that generalize across diseases, tissues and modalities.

Archy, founded in 2021 in San Jose, USA, provides dental clinics with an AI-driven all-in-one practice management system.

Valius Sciences is a San Francisco-based precision-oncology diagnostics company that launched in early 2026 with a "maximalist" approach to cancer diagnostics. It profiles each tumor across every biological layer (DNA, RNA and protein) to map all actionable therapeutic targets, target heterogeneity and resistance mechanisms, benchmarked against large tumor datasets. Rather than a static PDF report, Valius delivers interactive software and shareable data to clinicians and patients ("partnerships, not PDFs"). Founded by CEO Edward Larkin (who built Palantir's healthcare business and led life-sciences investing at Dragoneer), COO Claire Oldfield, and Head of Translational Science Sarah Hesse (ex-Takeda, ex-Intellia computational biologist, MIT bioengineering PhD).

Helical, founded in 2024 in Luxembourg, converts biological AI foundation models into reproducible drug discovery workflows for pharmaceutical teams.

AI-native drug discovery using patient-derived disease models to design small-molecule therapies for cancer and fibrosis.